The great “muddle-through” economy continued in earnest during October as all signs pointed to a US economy moving along at a moderate rate of growth, giving the Fed ample leeway to take a measured approach to interest rate recalibrations.

As frustrating as these low interest rates are to many savers, they continue to spur economic activity, whether it be corporate M&A, new home sales or borrowing to buy a new car.

December’s anticipated quarter-point move will likely do little to derail this steady, if unspectacular economic expansion.

The US unemployment rate for September ticked up slightly to 5.0% from the prior month’s 4.9%, with nonfarm payrolls expanding by +156,000, below estimates of +172,000. Private payrolls grew by +167,000 while manufacturing saw a decline of -13,000 jobs.

Average hourly earnings ticked up +0.2% MoM and +2.6% YoY while the average work week held steady at 34.4 hours. The Labor Force Participation rate climbed slightly to 62.9% while Initial Jobless Claims dipped below 250,000, continuing the long downward trend in this data series.

Prices crept higher in September with the Producer Price Index registering a higher than expected +0.3% MoM rise (+0.7% rise YoY) while the core measure of wholesale prices (ex-food & energy) ticked up +0.2% MoM and +1.2% YoY. At the consumer level, prices rose +0.3% MoM and +1.5% YoY while core CPI edged up +0.1% MoM and +2.2% YoY.

The Fed’s preferred measure of inflation, so-called Core PCE or the Personal Consumption Expenditure measure, edged up 0.2% in September and is up +1.7% YoY, darn close to the Fed’s +2.0% target. The one area of the economy that appears most at risk is the manufacturing sector.

Aside from the job losses mentioned above, Durable Goods Orders for September fell -0.1%, after rising just +0.1% in August. Industrial Production rose a meager +0.1% last month while Capacity Utilization came in at 75.4%, about a percentage point below the 10-year average for this indicator which measures the US’s capacity to produce goods and services.

Lastly, and on a bit of a positive note, the Markit US Manufacturing PMI for September came in at 51.5 while the preliminary reading for October showed a rise to 53.2, meaningfully above expectations.

Domestic Equity

All three S&P Market Cap Indices fell this month, with Large-, Mid-, and Small- declining -1.82%, -2.67%, and -4.48%, respectively.

Mid-Cap stocks, as measured by the S&P 400 Index, took leadership among it’s market cap peers this month, with a total year to date return of +9.40%.

Large-Caps trailed, only up by +5.87%, while Small-Caps were a close second at +8.77%. Value Stocks, as measured by the S&P 500 Citi Value Index, fell -1.51% in October, bringing the year to date performance of the index to +7.71%.

Growth stocks reversed last month’s trend, underperforming Value stocks by -61 bps. Value widened it’s year to date outperformance over Growth stocks by more than 350 bps.

Valuations contracted over the last month but continue to look in-line or slightly expensive relative to long term averages.

Small-Cap stocks, currently trading at 23.4x trailing earnings, look to be the cheapest compared to the long term average of 22.9x. From a sector standpoint, Financials and Utilities were the only positive performing sectors in October, rising +2.3% and +0.9%, respectively.

Financials continue to rise on the ever-increasing Fed rate hike expectations, which should be a boon to bank earnings. Energy still leads the other sectors this year, climbing just over +15% year to date. WTI Crude Oil fell -3% in the quarter, closing the month at $46.89/bbl, lower than the 52 week high of $51.60/bbl observed on 10/19. Oil is up +26.5% this year, aiding Energy company earnings and lowering the likelihood of defaults within the sector.

Health Care and Telecoms were the worst performers this month, declining -6.53% and -6.47%, respectively. Health Care is the only sector with negative performance for the year, falling -5.25%. Drug pricing concerns that have been made a priority for politicians, failed drug trials, and the rise of generic drugs have weighed heavily on this sector.

The Biotechnology Industry group, which represents around 20% of the Health Care sector, is down just shy of -17% this year. Verizon’s falling subscriber base, along with AT&T’s recent bid to merge with Time Warner, hurt Telecom’s performance on the month. Verizon and AT&T are down -6.4% and -8.3% MoM, respectively.

International Equity

International equity markets were broadly negative on the month, with the MSCI EAFE Index down -2.03%, while Emerging Markets, as measured by the MSCI EM Index managed to eke out a +0.25% gain.

On a country specific basis, Japan, China, and the United Kingdom outperformed their respective indices, gaining +5.93%, +3.19%, and +1.03% during the period.

At a regional level, the Eurozone, as measured by the MSCI EMU Index gained +1.38%; however, the region is still down -1.19% year to date, and has underperformed broad developed international equity markets.

At the sector level, MSCI ACWI ex U.S. sectors were mostly negative, led lower by Health Care, which lost -7.05% during the period as Novo Nordisk, a Denmark-listed pharmaceutical company, ushered in new wave of uncertainty surrounding drug price increases.

Subscribe to our free daily newsletters!
Please enter your email address to subscribe to ETF Trends' newsletters featuring latest news and educational events.